title: Prospective randomized trial comparing the efficacy of single 6-ml injection of hylan G-F 20 and hyaluronic acid for primary knee arthritis: a preliminary study.
abstract: OBJECTIVE
  To compare the efficacy of single 6-ml intraarticular injection between hylan G-F 20 and hyaluronic acid (HA) for knee osteoarthritis.
  
  
  METHODS
  Thirty-two patients with primary knee arthritis, who were randomly received single intraarticular injection of 6-ml hylan G-F 20 (Synvisc) or HA (Hyalgan), were prospectively evaluated for clinical outcomes at a minimum 26-week follow-up. The parameters, including visual analog scale (VAS) during walking, the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and Short-Form 36 (SF-36) questionnaires, were evaluated at pre-injection, then at 1 week, 4 weeks, 8 weeks, 12 weeks and 26 weeks, post-injection.
  
  
  RESULTS
  There were 15 patients in both groups who were available for final follow-up with no statistical differences in demographic data, VAS during walking, WOMAC score and SF-36 score at pre-injection. There was no adverse event related to viscosupplementation using in is better than of both agents. At 26-week follow-up, patients in both groups had significantly improved VAS during walking (p < 0.01), WOMAC score (p < 0.01) and SF-36 (p < 0.05) with no statistical differences between groups. However the cost of hylan G-F 20 was much more expensive than that of HA (534 USD vs. 252 USD).
  
  
  CONCLUSIONS
  A single intraarticular injection of both hylan G-F 20 and HA for primary knee arthritis had no adverse event related to 6-ml volume. At 26-week follow-up of the present preliminary study, both groups had similarly improved clinical outcomes post-injection. Further study in larger population is required. As the cost of hylan G-F 20 was 2 times higher than HA, a single 6-ml intraarticular injection of HA (Hyalgan) provided better cost-effectiveness than hylan G-F 20 (Synvisc).
authors: Department of Orthopaedics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
authors: Yutthana
authors: Y
authors: Khanasuk
authors: Teerayut
authors: T
authors: Dechmaneenin
authors: Aree
authors: A
authors: Tanavalee
mesh_terms: D000368:Aged; D001672:Biocompatible Materials / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000191:economics; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D011446:Prospective Studies; D055676:Viscosupplementation / Q000191:economics / Q000379:methods*; D055675:Viscosupplements / Q000008:administration & dosage* / Q000191:economics
chemical_list: D001672:Biocompatible Materials; D055675:Viscosupplements; C049816:hylan; D006820:Hyaluronic Acid